New pill could boost weight loss, study launches
Disease control
Not yet recruiting
This phase 2 study tests an experimental oral drug, NA-931, alone or with an approved injectable weight-loss medication (tirzepatide), in 224 overweight or obese adults aged 18-80. The main goal is to see how much weight participants lose over 48 weeks compared to placebo. The st…
Phase: PHASE2 • Sponsor: Biomed Industries, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC